Although this study identified NAT10 as a novel factor that inhibits ferroptosis in renal clear cell carcinoma via the NFE2L1-GPX4 axis, there are some limitations that need to be acknowledged: (a) Clinical sample limitations: our cohort included 30 paired pairs of renal clear cell carcinoma samples with limited clinicopathological stratification (e.g., only 35% stage III–IV and 20% high-grade tumors). This evidence concerns the gene GPX4 and clear cell renal carcinoma.